Show simple item record

AuthorSid Ahmed, Mazen
AuthorAbdel Hadi, Hamad
AuthorHassan, Abubaker
AuthorAbu Jarir, Sulieman
AuthorAl-Maslamani3, Muna
AuthorEltai, Nahla
AuthorDousa, Khalid
AuthorHujer, Andrea
AuthorSultan, Ali
AuthorSoderquis, Bo
AuthorBonomo7, Robert
AuthorIbrahim1, Emad
AuthorJass, Jana
AuthorOmrani, Ali
Available date2019-09-18T05:52:27Z
Publication Date2019-09-03
Publication NameJournal of Antimicrobial Chemotherapyen_US
Identifierhttp://dx.doi.org/10.1093/jac/dkz379
CitationMazen A Sid Ahmed, Hamad Abdel Hadi, Abubaker A I Hassan, Sulieman Abu Jarir, Muna A Al-Maslamani, Nahla Omer Eltai, Khalid M Dousa, Andrea M Hujer, Ali A Sultan, Bo Soderquist, Robert A Bonomo, Emad Bashir Ibrahim, Jana Jass, Ali S Omrani, Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar, Journal of Antimicrobial Chemotherapy, , dkz379, https://doi.org/10.1093/jac/dkz379
ISSN0305-7453
URIhttp://hdl.handle.net/10576/11880
AbstractObjectives: To investigate the in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against clinical isolates of MDR Pseudomonas aeruginosa from Qatar, as well as the mechanisms of resistance. Methods: MDR P. aeruginosa isolated between October 2014 and September 2015 from all public hospitals in Qatar were included. The BD PhoenixTM system was used for identification and initial antimicrobial susceptibility testing, while Liofilchem MIC Test Strips (Liofilchem, Roseto degli Abruzzi, Italy) were used for confirmation of ceftazidime/avibactam and ceftolozane/tazobactam susceptibility. Ten ceftazidime/avibactam- and/or ceftolozane/tazobactam-resistant isolates were randomly selected for WGS. Results: A total of 205 MDR P. aeruginosa isolates were included. Of these, 141 (68.8%) were susceptible to cef- tazidime/avibactam, 129 (62.9%) were susceptible to ceftolozane/tazobactam, 121 (59.0%) were susceptible to both and 56 (27.3%) were susceptible to neither. Twenty (9.8%) isolates were susceptible to ceftazidime/avibac- tam but not to ceftolozane/tazobactam and only 8 (3.9%) were susceptible to ceftolozane/tazobactam but not to ceftazidime/avibactam. Less than 50% of XDR isolates were susceptible to ceftazidime/avibactam or ceftolo- zane/tazobactam. The 10 sequenced isolates belonged to six different STs and all produced AmpC and OXA enzymes; 5 (50%) produced ESBL and 4 (40%) produced VIM enzymes. Conclusions: MDR P. aeruginosa susceptibility rates to ceftazidime/avibactam and ceftolozane/tazobactam were higher than those to all existing antipseudomonal agents, except colistin, but were less than 50% in ex- tremely resistant isolates. Non-susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam was largely due to the production of ESBL and VIM enzymes. Ceftazidime/avibactam and ceftolozane/tazobactam are pos- sible options for some patients with MDR P. aeruginosa in Qatar.
Languageen
PublisherOxford University Press
Subjectpseudomonas aeruginosa
Subjectceftazidime
Subjectqatar
Subjectenzymes
Subjecttazobactam
Subjectextended-spectrum beta lactamases
Subjectceftolozane
Subjectavibactam
Subjectwhole genome
Subjectsequencing
TitleEvaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar
TypeArticle
dc.identifier.essn 1460-2091


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record